Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Jung, A; Orenti, A; Dunlevy, F; Aleksejeva, E; Bakkeheim, E; Bobrovnichy, V; Carr, SB; Colombo, C; Corvol, H; Cosgriff, R; Daneau, G; Dogru, D; Drevinek, P; Vukic, AD; Fajac, I; Fox, A; Fustik, S; Gulmans, V; Harutyunyan, S; Hatziagorou, E; Kasmi, I; Kayserová, H; Kondratyeva, E; Krivec, U; Makukh, H; Malakauskas, K; McKone, EF; Mei-Zahav, M; de, Monestrol, I; Olesen, HV; Padoan, R; Parulava, T; Pastor-Vivero, MD; Pereira, L; Petrova, G; Pfleger, A; Pop, L; van, Rens, JG; Rodic, M; Schlesser, M; Storms, V; Turcu, O; Woz, Niacki, L; Yiallouros, P; Zolin, A; Downey, DG; Naehrlich, L.
Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe.
ERJ Open Res. 2021; 7(4):
Doi: 10.1183/23120541.00411-2021
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Pfleger Andreas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in people with cystic fibrosis (pwCF) can lead to severe outcomes. Methods: In this observational study, the European Cystic Fibrosis Society Patient Registry collected data on pwCF and SARS-CoV-2 infection to estimate incidence, describe clinical presentation and investigate factors associated with severe outcomes using multivariable analysis. Results: Up to December 31, 2020, 26 countries reported information on 828 pwCF and SARS-CoV-2 infection. Incidence was 17.2 per 1000 pwCF (95% CI: 16.0-18.4). Median age was 24 years, 48.4% were male and 9.4% had lung transplants. SARS-CoV-2 incidence was higher in lung-transplanted (28.6; 95% CI: 22.7-35.5) versus non-lung-transplanted pwCF (16.6; 95% CI: 15.4-17.8) (p≤0.001).SARS-CoV-2 infection caused symptomatic illness in 75.7%. Factors associated with symptomatic SARS-CoV-2 infection were age >40 years, at least one F508del mutation and pancreatic insufficiency.Overall, 23.7% of pwCF were admitted to hospital, 2.5% of those to intensive care, and regretfully 11 (1.4%) died. Hospitalisation, oxygen therapy, intensive care, respiratory support and death were 2- to 6-fold more frequent in lung-transplanted versus non-lung-transplanted pwCF.Factors associated with hospitalisation and oxygen therapy were lung transplantation, cystic fibrosis-related diabetes (CFRD), moderate or severe lung disease and azithromycin use (often considered a surrogate marker for Pseudomonas aeruginosa infection and poorer lung function). Conclusion: SARS-CoV-2 infection yielded high morbidity and hospitalisation in pwCF. PwCF with forced expiratory volume in 1 s <70% predicted, CFRD and those with lung transplants are at particular risk of more severe outcomes.